EAHP learning modules
A number of modules for self-assessment are now available online via BMJ Learning. Aimed at hospital pharmacists and based on recordings of satellite events held at the annual European Association of Hospital Pharmacists (EAHP) Congress, they are free to access and accredited by the Accreditation Council for Pharmacy Education (ACPE).
The events were financially supported by different external organisations but totally independent of industry involvement, with the faculty and the topics selected by the EAHP scientific committee.
All users must complete a one-time registration on BMJ Learning and subsequently log in on every visit using their username and password to access modules and their CPD record. Accreditation is only valid for 2 years from the date of publication. Printable CPD certificates are available to users that achieve the minimum pass mark and complete a survey at the end of the course. 1.5-2 ACPE credits will be awarded, depending on the length of the course.
Oral anticoagulant therapy is used to reduce the risk of stroke in patients with atrial fibrillation (AF) and pharmacists have an important role in educating patients about and managing treatment with oral anticoagulants. In this course three pharmacist practitioners members of iPACT (International Pharmacists for Anticoagulation Care Taskforce) present projects outlining how oral anticoagulants can be employed to improve the care of patients suffering from AF.
Optimal oral anticoagulant therapy requires careful consideration of patient’s needs and an understanding of the efficacy, safety, pharmacokinetics of the anticoagulants and the methods used to measure their effects. This course enables pharmacists to stay updated with new anticoagulant drugs, educate patients about their drugs, and highlight the importance of adhering to anticoagulant therapy.
Biologicals and biosimilars
Provides the key information on biosimilar approval in the EU as applied to cancer therapy. By understanding the concepts and facts, hospital pharmacists will be enabled to provide a scientific, unbiased approach with a focus on patient care in a world of limited resources. By gaining insights on into the regulatory assessment process and the clinician’s perspective in prescribing biosimilars, the ability of hospital pharmacists to advise on how to implement biosimilars of monoclonal antibodies used in cancer therapy will be strengthened.
Offers insights into the evolution of biologicals, which are an essential treatment option for a variety of diseases in current medicine. Course participants will learn about the development and authorisation of biosimilars as well as the quality criteria of biologicals. In addition, issues of switching and interchangeability of biologicals will be addressed to provide an in-depth understanding of key principles regarding quality, safety and efficacy.
Biosimilars of targeted breast cancer biologic drugs will soon be introduced into the market, and it will be essential for hospital pharmacists to understand the key concepts in order to manage their implementation. This module gives pharmacists a better understanding of the biosimilar approval process in the EU, the role of biosimilars in reducing therapeutic cost in breast cancer, and how to work with other healthcare providers, stakeholders and patients to manage their implementation.